Abstracts tagged "ANCA"

Abstract Number: 2700 • 2012 ACR/ARHP Annual Meeting
A Multi-Center Study of the Appropriateness of Anti-Neutrophilic Cytoplasmic Antibody Testing
Tarun S. Sharma¹, Vikash Sinha², Vino Unson², Saurav Acharya³, Sahar Mohammadi² and Amer Syed², ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Internal Medicine, Mount.Sinai School of Medicine-Jersey City Medical Center, Jersey City, NJ, ³Internal Medicine, Jersey City Medical Center-Barnabas Health, Jersey City, NJ
A Multi-Center Study of the Appropriateness of Anti-Neutrophilic Cytoplasmic Antibody TestingBackground/Purpose: Anti Neutrophil Cytoplasmic Antibody (ANCA) test is an Indirect Immunoflorescence test used as an…
Abstract Number: 1774 • 2012 ACR/ARHP Annual Meeting
Identification of Target Antigens of Anti-Endothelial Cell Antibodies in Patients with ANCA-Associated Systemic Vasculitis: A Proteomic Approach
Alexis Régent¹, Hanadi Dib², Guillaume Bussone¹, Mathieu C. Tamby¹, Nicolas Tamas², Christian Federici³, Cédric Broussard³, Loic Guillevin⁴ and Luc Mouthon¹, ¹Internal Medicine, Hopital Cochin, Paris, France, ²Université Paris Descartes, Paris, France, ³Institut Cochin, INSERM U1016, CNRS UMR 8104, Université Paris Descartes, Paris, France, ⁴Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Anti-endothelial cell antibodies (AECA) are frequently detected in anti-neutrophil cytoplasm antibodies (ANCA)-associated systemic vasculitis (AAV) and are considered to play pathological roles but their…
Abstract Number: 1652 • 2012 ACR/ARHP Annual Meeting
Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
Loic Guillevin¹, Christian Pagnoux², Alexandre Karras³, Chahera Khoutra⁴, Olivier Aumaitre⁵, Pascal Cohen⁶, Francois Maurier⁷, Olivier Decaux⁸, Hélène Desmurs-Clavel⁹, Pierre Gobert¹⁰, Thomas Quemeneur¹¹, Claire Blanchard-Delaunay¹², Pascal Godmer¹³, Xavier Puechal¹⁴, Pierre-Louis Carron¹⁵, Pierre yves Hatron¹⁶, Nicolas Limal¹⁷, Mohamed Hamidou¹⁸, Maize Ducret¹⁹, Florence Vende²⁰, Elisa Pasqualoni²¹, Bernard Bonnotte²², Philippe Ravaud²³, Luc Mouthon²⁴ and French Vasculitis Study Group (FVSG)²⁵, ¹Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ²Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ³Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁴Pneumology, Hospices Civils de Lyon, Hôpital Louis Pradel, Lyon, France, ⁵Department of Internal Medicine, Centre Hospitalier de Clermont-Ferrand, Clermont-Ferrand, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁷HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁸Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁹Internal Medicine, Hospices Civils de Lyon, Hôpital Louis Pradel, Lyon, France, ¹⁰Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹¹Internal medicine, CHR de Valenciennes, Valenciennes, France, ¹²Internal Medicine, Centre Hospitalier, Niort, France, ¹³Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ¹⁴Internal Medicine, Hôpital Cochin, Paris, France, ¹⁵Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, ¹⁶Department of Internal Medicine, Hôpital Claude Huriez, Université Lille II, Lille, France, Paris, France, ¹⁷Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, ¹⁸Internal Medicine Department, Nantes University Hospital, Nantes, France, ¹⁹Department of Internal Medicine, Centre Hospitalier d'Annecy, Annecy, France, ²⁰Nephrology, Hôpital Bicbat, APHP, Paris, France, ²¹Department of Internal Medicine, Hôpital Bicbat, APHP, Paris, France, ²²Department of Internal Medicine, Centre Hospitalier de Dijon, Dijon, France, ²³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ²⁴Internal Medicine, Hopital Cochin, Paris, France, ²⁵Internal Medicine, Hôpital Cochin, Université Paris–Descartes, Paris, France
Background/Purpose: Once ANCA-associated vasculitis (AAV) remission has been achieved with CS and cyclophosphamide (CYC), maintenance therapy usually relies on azathioprine (AZA) or methotrexate. However, 18-…
Abstract Number: 1654 • 2012 ACR/ARHP Annual Meeting
Primary Endpoint Failure in the Rituximab in ANCA-Associated Vasculitis Trial
Eli Miloslavsky¹, Ulrich Specks², John H. Stone³ and RAVE/ITN Research Group⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Mayo Clinic, Rochester, MN, ³Rheumatology, Massachusetts General Hospital, Boston, MA, ⁴Bethesda, MD
Primary Endpoint Failure in the Rituximab in ANCA-associated Vasculitis TrialBackground/Purpose: The RAVE trial demonstrated that rituximab (RTX) is non-inferior to cyclophosphamide (CYC) for remission induction…
Abstract Number: 1538 • 2012 ACR/ARHP Annual Meeting
ANCA-Associated Vasculitis in Hispanic Americans: An Unrecognized Severity
Ranadeep Mandhadi¹, Fadi Aldaghlawi², Asad Khan², Vajiha Irshad³, Joel A. Block² and Antoine Sreih⁴, ¹Mount Sinai Hospital, Chicago, IL, ²Rush University Medical Center, Chicago, IL, ³Internal Medicine, Stroger Hospital of Cook County, Chicago, IL, ⁴Medicine/Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: ANCA-associated vasculitis, once a disease thought to predominate in Caucasians, is now increasingly recognized in diverse ethnic populations. However, there has been little systematic…
Abstract Number: 1541 • 2012 ACR/ARHP Annual Meeting
Does Leflunomide Have a Place As Remission Maintenance Therapy in ANCA-Associated Vasculitis? A Bayesian Network Meta-Analysis with Hypothesis Driven Sensitivity Analyses to Adjust for Potential Biases
Glen S. Hazlewood¹, Claudia Metzler², George A. Tomlinson³, Wolfgang L. Gross⁴, Brian M. Feldman⁵, Loic Guillevin⁶ and Christian Pagnoux⁷, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²University of Lubeck, Bad Branstedy, Germany, ³University of Toronto, Toronto, ON, Canada, ⁴Dept of Clinical Rheumatology, Medical University at Lubeck, Lubeck, Germany, ⁵Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Internal Medicine, Cochin University Hospital, Paris, France, ⁷Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Primary: To determine the relative treatment effects of maintenance therapy in adult patients with ANCA-associated vasculitis who have achieved remission, using a Bayesian network…
Abstract Number: 1542 • 2012 ACR/ARHP Annual Meeting
The Efficacy of Rituximab Vs Cyclophosphamide for Treatment of Renal Disease in ANCA-Associated Vasculitis: The RAVE Trial Geetha D, Fervenza FC for the RAVE-Itn Research Group
Duvuru Geetha¹ and Fernando Fervenza², ¹Nephrology, Johns Hopkins University, Baltimore, MD, ²Mayo Clinic, Rochester, MN
Background/Purpose: Rituximab (RTX) is non-inferior to cyclophosphamide (CYC) followed by azathioprine (AZA) for remission-induction in severe ANCA associated vasculitis (AAV) but details of outcomes among…
Abstract Number: 1543 • 2012 ACR/ARHP Annual Meeting
Rituximab for ANCA-Associated Vasculitis: A Meta-Analysis of Randomized Trials
Carolina Mejia¹ and Carlos J. Lozada², ¹Internal Medicine, Mount Sinai Medical Center, Miami, FL, ²Dept of Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL
Background/Purpose: Over the past 40 years, cyclophosphamide/glucocorticoids combination therapy has been the standard regimen for remission induction in ANCA-associated vasculitis.. Although a major advance in…
Abstract Number: 1545 • 2012 ACR/ARHP Annual Meeting
Long-Term Follow-up of 118 Polyarteritis Nodosa and Microscopic Polyangiitis without Poor-Prognosis Factors
Maxime Samson¹, Xavier Puechal², Hervé Devilliers³, Camillo Ribi⁴, Pascal Cohen⁵, Boris Bienvenu⁶, Christian Pagnoux⁷, Luc Mouthon⁸, Loic Guillevin⁹ and French Vasculitis Study Group FVSG¹⁰, ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France; Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²Internal Medicine, Hôpital Cochin, Paris, France, ³Internal medicine, Hôpital Général, Dijon, France, ⁴Internal Medicine, Hôpital Universitaire Cantonal de Genève, Geneve, Switzerland, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁶Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, Caen, France, ⁷Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ⁸Internal Medicine, Hopital Cochim, Paris, France, ⁹Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ¹⁰Internal Medicine, Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, 75005 Paris, France., Paris, France
Background/Purpose: Polyarteritis nodosa (PAN) and microscopic polyangiitis (MPA) are 2 vasculitides characterized by necrotizing inflammation of the vessel wall. They share several clinical features and…
Abstract Number: 1524 • 2012 ACR/ARHP Annual Meeting
The Use of the International Classification of Function, Disability and Health As a Conceptual Framework for Comparison of the Content of Core Outcome Instruments with the Patient Perspective in Vasculitis
Nataliya Milman¹, Peter A. Merkel², Annelies Boonen³, Lee Strunin⁴, Ryan Borg⁴ and Peter Tugwell⁵, ¹Rheumatology, Ottawa Hospital, Riverside Campus, Ottawa, ON, Canada, ²University of Pennsylvania, Philadelphia, PA, ³Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Community Health Sciences, Boston University School of Public Health, Boston, MA, ⁵Institute of Population Health, Center For Global Health, University of Ottawa, Ottawa General Hospital, Ottawa, ON, Canada
Background/Purpose: The International Classification of Functioning, Disability and Health (ICF) is a general health model endorsed by the World Health Organization. It describes health along…
Abstract Number: 1531 • 2012 ACR/ARHP Annual Meeting
Comparative Proteomic Analysis of Neutrophils Between Microscopic Polyangiitis and Granulomatosis with Polyangiitis
Teisuke Uchida¹, Kouhei Nagai², Toshiyuki Sato², Mitsumi Arito², Nobuko Iizuka², Manae Kurokawa², Naoya Suematsu², Kazuki Okamoto², Shoichi Ozaki³ and Tomohiro Kato⁴, ¹Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine,, Kawasaki, Japan, ²Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, Kawasaki, Japan, ³Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Clinical Proteomics and Molecular Medicine, St. Mariannna University Graduate School of Medicine., Kawasaki, Japan
Background/Purpose: Both microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) belong to ANCA-associated vasculitis (AAV), in which dysfunction of polymorphonuclear cells (PMN) is thought to…
Abstract Number: 1532 • 2012 ACR/ARHP Annual Meeting
Serum Angiopoietin-2 Level Reflects the Disease Activity and Renal Function in Antineutrophilic Cytoplasmic Antibody-Associated Vasculitis
Yoko Wada¹, Hiroe Sato¹, Takeshi Nakatsue¹, Shuichi Murakami¹, Takeshi Kuroda², Masaaki Nakano³ and Ichiei Narita¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²Health Administration Center, Niigata University, Niigata, Japan, ³School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan
Background/Purpose: Angiopoietin-2 (Ang-2) has emerged as a key mediator of endothelial cell activation. Ang-1 and Ang-2 are antagonistic ligands which bind with similar affinity to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].